Trinity Biotech plc (TRIB) 10-Year Financial Performance & Capital Metrics

TRIB • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

AboutTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.Show more

Revenue $62M +8.3%
EBITDA -$19M +23.6%
Net Income -$32M -32.4%
EPS (Diluted) -1.77 +44.7%
Gross Margin 34.83% +1.8%
EBITDA Margin -31.35% +29.5%
Operating Margin -34.38% +27.7%
Net Margin -51.64% -22.2%
ROE -
ROIC -31.68% +19.4%
Debt/Equity -
Interest Coverage -2.21 +17.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 7.4% over 5 years
✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-5.19%

5Y-7.41%

3Y-8.8%

TTM-15.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM8.21%

ROCE

10Y Avg-9.51%

5Y Avg-21.65%

3Y Avg-38.26%

Latest-36.62%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	100.19M	99.61M	99.14M	97.03M	90.44M	101.98M	81.15M	62.52M	56.83M	61.55M
Revenue Growth %	-0.04%	-0.01%	-0%	-0.02%	-0.07%	0.13%	-0.2%	-0.23%	-0.09%	0.08%
Cost of Goods Sold+	53.95M	56.52M	57.25M	55.59M	52.31M	53.4M	54.89M	52.73M	37.38M	40.11M
COGS % of Revenue	0.54%	0.57%	0.58%	0.57%	0.58%	0.52%	0.68%	0.84%	0.66%	0.65%
Gross Profit+	46.24M	43.09M	41.89M	41.45M	38.12M	48.58M	33.45M	22.05M	19.45M	21.44M
Gross Margin %	0.46%	0.43%	0.42%	0.43%	0.42%	0.48%	0.41%	0.35%	0.34%	0.35%
Gross Profit Growth %	-0.08%	-0.07%	-0.03%	-0.01%	-0.08%	0.27%	-0.31%	-0.34%	-0.12%	0.1%
Operating Expenses+	32.8M	35.6M	36.41M	34.77M	32.82M	48.5M	29.52M	32.96M	46.49M	42.61M
OpEx % of Revenue	0.33%	0.36%	0.37%	0.36%	0.36%	0.48%	0.36%	0.53%	0.82%	0.69%
Selling, General & Admin	28.02M	30.8M	30.85M	29.5M	27.58M	25.07M	24.68M	29.17M	31.15M	28.82M
SG&A % of Revenue	0.28%	0.31%	0.31%	0.3%	0.31%	0.25%	0.3%	0.47%	0.55%	0.47%
Research & Development	5.07M	5.04M	5.66M	5.37M	5.33M	5.08M	4.5M	4.14M	4.38M	4.54M
R&D % of Revenue	0.05%	0.05%	0.06%	0.06%	0.06%	0.05%	0.06%	0.07%	0.08%	0.07%
Other Operating Expenses	0	0	-100K	-102K	-91K	18.34M	336K	-343K	10.96M	9.25M
Operating Income+	13.45M	7.49M	5.48M	3.3M	872K	82K	3.94M	-15.27M	-27.05M	-21.16M
Operating Margin %	0.13%	0.08%	0.06%	0.03%	0.01%	0%	0.05%	-0.24%	-0.48%	-0.34%
Operating Income Growth %	-0.25%	-0.44%	-0.27%	-0.4%	-0.74%	-0.91%	47.02%	-4.88%	-0.77%	0.22%
EBITDA+	19.09M	13.32M	10.68M	7.42M	5.77M	3.16M	6.68M	-12.94M	-25.27M	-19.3M
EBITDA Margin %	0.19%	0.13%	0.11%	0.08%	0.06%	0.03%	0.08%	-0.21%	-0.44%	-0.31%
EBITDA Growth %	-0.15%	-0.3%	-0.2%	-0.31%	-0.22%	-0.45%	1.12%	-2.94%	-0.95%	0.24%
D&A (Non-Cash Add-back)	5.64M	5.82M	5.2M	4.12M	4.89M	3.08M	2.74M	2.33M	1.78M	1.86M
EBIT	27M	-36.74M	-34.47M	-18.1M	-23.41M	118K	7.85M	-19.05M	-25.87M	-18.77M
Net Interest Income+	9.44M	-2.29M	-4.6M	-2.96M	-5.12M	-6.71M	-5.87M	-24.43M	-8.98M	-9.56M
Interest Income	12.91M	2.43M	808K	2.12M	464K	36K	1.22M	303K	1.17M	0
Interest Expense	3.48M	4.73M	5.41M	5.08M	5.58M	6.75M	7.1M	24.73M	10.15M	9.56M
Other Income/Expense	9.49M	-2.26M	-2.21M	-2.96M	-5.88M	-6.71M	-5.86M	-24.43M	-9.88M	-9.56M
Pretax Income+	22.88M	5.19M	1.6M	3.03M	821K	-6.63M	-1.92M	-43.78M	-36.93M	-30.73M
Pretax Margin %	0.23%	0.05%	0.02%	0.03%	0.01%	-0.07%	-0.02%	-0.7%	-0.65%	-0.5%
Income Tax+	1.08M	41K	-697K	637K	4.89M	-620K	-74K	-194K	-59K	486K
Effective Tax Rate %	0.95%	-19.37%	-25.11%	0.79%	-4.95%	0.96%	-0.45%	0.94%	0.65%	1.03%
Net Income+	21.8M	-100.63M	-40.27M	2.39M	-4.07M	-6.39M	875K	-41M	-24.02M	-31.79M
Net Margin %	0.22%	-1.01%	-0.41%	0.02%	-0.04%	-0.06%	0.01%	-0.66%	-0.42%	-0.52%
Net Income Growth %	0.27%	-5.62%	0.6%	1.06%	-2.7%	-0.57%	1.14%	-47.86%	0.41%	-0.32%
Net Income (Continuing)	22.19M	-38.56M	-38.66M	-22.66M	0	-6.01M	-1.85M	-43.59M	-36.87M	-31.22M
Discontinued Operations	0	0	0	568K	77K	-375K	2.73M	2.58M	12.85M	-573K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.48	-17.78	-7.49	0.46	-0.80	-1.54	0.16	-5.20	-3.20	-1.77
EPS Growth %	-0.34%	-38.04%	0.58%	1.06%	-2.74%	-0.93%	1.1%	-33.5%	0.38%	0.45%
EPS (Basic)	0.96	-21.91	-9.31	0.57	-0.97	-1.54	0.21	-6.00	-3.20	-1.77
Diluted Shares Outstanding	5.48M	5.66M	5.38M	5.18M	5.09M	4.18M	5.33M	7.77M	7.65M	17.96M
Basic Shares Outstanding	4.63M	4.59M	4.32M	4.18M	4.18M	4.18M	4.18M	6.75M	7.65M	17.96M
Dividend Payout Ratio	0.23%	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	163.23M	133.49M	112.59M	86.66M	71.39M	83.3M	72.69M	46.67M	39.04M	41.12M
Cash & Short-Term Investments	101.95M	77.11M	57.61M	30.28M	16.4M	27.33M	25.91M	6.58M	3.69M	5.17M
Cash Only	101.95M	77.11M	57.61M	30.28M	16.4M	27.33M	25.91M	6.58M	3.69M	5.17M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	20.66M	20.16M	21.29M	25.22M	22.39M	24.59M	15.71M	15.65M	13.38M	14.6M
Days Sales Outstanding	75.25	73.86	78.38	94.86	90.38	88.03	70.66	91.39	85.94	86.6
Inventory	35.13M	32.59M	32.8M	30.36M	32.02M	30.22M	29.12M	22.5M	19.93M	19.37M
Days Inventory Outstanding	237.64	210.46	209.15	199.35	223.41	206.55	193.67	155.76	194.63	176.29
Other Current Assets	0	0	0	0	0	0	0	1K	0	0
Total Non-Current Assets+	195.73M	116.1M	80.02M	64.57M	59.68M	47.1M	46.21M	45.44M	20.39M	62.17M
Property, Plant & Equipment	20.66M	13.4M	5.8M	5.36M	9.29M	8.55M	5.92M	5.68M	1.89M	4.62M
Fixed Asset Turnover	4.85x	7.43x	17.09x	18.10x	9.73x	11.93x	13.71x	11.00x	30.04x	13.32x
Goodwill	52.69M	25.77M	17.9M	16.14M	12.59M	12.59M	12.54M	12.54M	0	13.84M
Intangible Assets	108.67M	61.5M	46.86M	36.81M	31.06M	21.27M	23.44M	22.73M	16.27M	37.5M
Long-Term Investments	5.56M	792.35K	1.04M	476K	403K	441K	151K	212K	214K	2.46M
Other Non-Current Assets	-4.61M	77.65K	-274K	82K	82K	64K	56K	55K	43K	194K
Total Assets+	358.96M	249.59M	192.62M	151.24M	131.07M	130.4M	118.89M	92.1M	59.44M	103.29M
Asset Turnover	0.28x	0.40x	0.51x	0.64x	0.69x	0.78x	0.68x	0.68x	0.96x	0.60x
Asset Growth %	0.48%	-0.3%	-0.23%	-0.21%	-0.13%	-0.01%	-0.09%	-0.23%	-0.35%	0.74%
Total Current Liabilities+	20.11M	25.28M	21.23M	17.6M	19.45M	27.06M	100.49M	17.34M	15.04M	32.09M
Accounts Payable	8.33M	9.02M	8.04M	8.12M	7.83M	7.1M	6.76M	6.21M	3.88M	6.83M
Days Payables Outstanding	56.35	58.23	51.29	53.29	54.65	48.55	44.97	42.95	37.93	62.17
Short-Term Debt	0	0	0	0	2.4M	2.9M	83.31M	210K	210K	210K
Deferred Revenue (Current)	187K	224K	278K	312K	292K	1000K	141K	114K	50K	197K
Other Current Liabilities	598K	4.21M	201K	204K	-2.18M	760K	249K	153K	160K	2.57M
Current Ratio	8.12x	5.28x	5.30x	4.92x	3.67x	3.08x	0.72x	2.69x	2.60x	1.28x
Quick Ratio	6.37x	3.99x	3.76x	3.20x	2.02x	1.96x	0.43x	1.39x	1.27x	0.68x
Cash Conversion Cycle	256.54	226.09	236.23	240.91	259.14	246.03	219.35	204.2	242.63	200.71
Total Non-Current Liabilities+	124.96M	115.59M	106.19M	89.58M	106.91M	105.56M	18.72M	76.94M	68.35M	106.38M
Long-Term Debt	91.51M	92.23M	92.95M	81.38M	82.02M	82.69M	0	58.05M	54.65M	87.79M
Capital Lease Obligations	1.04M	732K	532K	526K	17.75M	16.59M	13.87M	12.27M	10.87M	10.48M
Deferred Tax Liabilities	24.82M	18.36M	10.83M	7.43M	7.14M	4.91M	4.86M	5.06M	2.3M	4.56M
Other Non-Current Liabilities	32.4M	22.62M	2.23M	8.09M	4K	1.37M	0	1.57M	526K	3.55M
Total Liabilities	145.07M	140.87M	127.42M	107.18M	126.36M	132.62M	119.21M	94.28M	83.38M	138.47M
Total Debt+	98.04M	96.49M	94.83M	81.62M	82.03M	104.34M	99.16M	72.2M	67.43M	100.76M
Net Debt	-3.91M	19.38M	37.22M	51.34M	65.63M	77.01M	73.25M	51.68M	63.74M	95.6M
Debt / Equity	0.46x	0.89x	1.45x	1.85x	17.40x	-	-	-	-	-
Debt / EBITDA	5.14x	7.25x	8.88x	11.00x	14.23x	33.03x	14.84x	-	-	-
Net Debt / EBITDA	-0.20x	1.46x	3.49x	6.92x	11.38x	24.38x	10.96x	-	-	-
Interest Coverage	3.86x	1.59x	1.01x	0.65x	0.16x	0.01x	0.55x	-0.62x	-2.67x	-2.21x
Total Equity+	213.89M	108.73M	65.2M	44.05M	4.71M	-2.22M	-319K	-2.18M	-23.95M	-35.18M
Equity Growth %	0.09%	-0.49%	-0.4%	-0.32%	-0.89%	-1.47%	0.86%	-5.82%	-10.01%	-0.47%
Book Value per Share	39.02	19.21	12.13	8.51	0.93	-0.53	-0.06	-0.28	-3.13	-1.96
Total Shareholders' Equity	213.89M	108.73M	65.2M	44.05M	4.71M	-2.22M	-319K	-2.18M	-23.95M	-35.18M
Common Stock	1.22M	1.22M	1.22M	1.22M	1.22M	1.21M	1.21M	1.96M	1.97M	4.19M
Retained Earnings	201.95M	93M	46.16M	24.37M	11.51M	10.57M	12.56M	-26.7M	-48.64M	-79.12M
Treasury Stock	-7.37M	-17.33M	-24.78M	-24.92M	-24.92M	-24.92M	-24.92M	-24.92M	-24.92M	-24.92M
Accumulated OCI	-4.81M	-1.69M	1.63M	2.27M	-24.21M	-5.27M	-5.36M	-5.69M	1.03M	-5.44M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	12.34M	13.77M	12.11M	6.93M	5.47M	23.75M	13.24M	-921K	-11.56M	-4.19M
Operating CF Margin %	0.12%	0.14%	0.12%	0.07%	0.06%	0.23%	0.16%	-0.01%	-0.2%	-0.07%
Operating CF Growth %	-0.22%	0.12%	-0.12%	-0.43%	-0.21%	3.34%	-0.44%	-1.07%	-11.55%	0.64%
Net Income	19.85M	16.25M	12.77M	13.07M	12.2M	-6.39M	875K	-41.01M	-24.02M	-31.79M
Depreciation & Amortization	5.64M	6.13M	5.2M	4.12M	4.89M	3.08M	2.74M	2.33M	1.78M	1.86M
Stock-Based Compensation	1.55M	1.41M	928K	1.37M	758K	792K	1.1M	1.75M	2.07M	1.32M
Deferred Taxes	1.08M	-8.63M	-374K	-1.11M	-1.01M	-182K	-167K	-192K	-59K	486K
Other Non-Cash Items	-8.63M	757K	-5.87M	-2.92M	-10.57M	22.31M	8.86M	37.85M	11.37M	17.74M
Working Capital Changes	-7.16M	-2.15M	-535K	-7.6M	-796K	4.14M	-172K	-1.66M	-2.69M	6.19M
Change in Receivables	-2.34M	738K	-2.37M	-5.96M	445K	-2.49M	6.24M	-966K	1.05M	-2.37M
Change in Inventory	-2.34M	-3.62M	-2.46M	1.99M	-2.96M	-3.42M	-4.41M	-877K	-971K	-1.74M
Change in Payables	-3.33M	1.27M	2.02M	-3.42M	151K	4.99M	-7.59M	181K	-2.77M	8.19M
Cash from Investing+	-22.72M	-22.28M	-16.37M	-17.29M	-15.36M	-10.2M	-8.69M	-5.98M	24.76M	-22.97M
Capital Expenditures	-22.72M	-22.28M	-16.37M	-17.29M	-15.36M	-10.2M	-8.69M	-5.98M	-803K	-405K
CapEx % of Revenue	0.23%	0.22%	0.17%	0.18%	0.17%	0.1%	0.11%	0.1%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.11M	-1.11M	-1.11M	-9.86M	0	0	0	0	-1.9M	-9.66M
Cash from Financing+	103.23M	-16.34M	-15.25M	-16.98M	-4M	-2.72M	-6.02M	-12.32M	-16.04M	28.81M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-5.1M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-6.67M	-3.75M	-4.6M	-4.5M	-463K	524K	-3.08M	-10.61M	-8.67M	-6.25M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.38M	-8.51M	-4.25M	-10.35M	-9.88M	13.56M	4.55M	-6.9M	-12.36M	-14.26M
FCF Margin %	-0.1%	-0.09%	-0.04%	-0.11%	-0.11%	0.13%	0.06%	-0.11%	-0.22%	-0.23%
FCF Growth %	-0.27%	0.18%	0.5%	-1.43%	0.05%	2.37%	-0.66%	-2.52%	-0.79%	-0.15%
FCF per Share	-1.89	-1.50	-0.79	-2.00	-1.94	3.24	0.85	-0.89	-1.61	-0.79
FCF Conversion (FCF/Net Income)	0.57x	-0.14x	-0.30x	2.90x	-1.35x	-3.72x	15.13x	0.02x	0.48x	0.13x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.61%	-62.38%	-46.31%	4.38%	-16.68%	-512.27%	-	-	-	-
Return on Invested Capital (ROIC)	5.07%	3.32%	3.56%	2.5%	0.79%	0.08%	4%	-16.79%	-39.3%	-31.68%
Gross Margin	46.16%	43.26%	42.25%	42.72%	42.15%	47.64%	41.23%	35.27%	34.22%	34.83%
Net Margin	21.75%	-101.02%	-40.62%	2.46%	-4.5%	-6.26%	1.08%	-65.58%	-42.26%	-51.64%
Debt / Equity	0.46x	0.89x	1.45x	1.85x	17.40x	-	-	-	-	-
Interest Coverage	3.86x	1.59x	1.01x	0.65x	0.16x	0.01x	0.55x	-0.62x	-2.67x	-2.21x
FCF Conversion	0.57x	-0.14x	-0.30x	2.90x	-1.35x	-3.72x	15.13x	0.02x	0.48x	0.13x
Revenue Growth	-4.46%	-0.58%	-0.47%	-2.12%	-6.8%	12.77%	-20.43%	-22.96%	-9.1%	8.31%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023
Point-of-Care	16.77M	14.84M	11.39M	9.21M	10.34M	9.21M	9.09M
Point-of-Care Growth	-	-11.55%	-23.21%	-19.12%	12.18%	-10.87%	-1.32%
Clinical laboratory goods	-	-	-	84.28M	74.7M	-	-
Clinical laboratory goods Growth	-	-	-	-	-11.37%	-	-
Clinical laboratory services	-	-	-	8.48M	7.93M	-	-
Clinical laboratory services Growth	-	-	-	-	-6.56%	-	-
Clinical laboratory	73.37M	71.62M	68.13M	-	-	-	-
Clinical laboratory Growth	-	-2.38%	-4.87%	-	-	-	-
Laboratory services	9M	10.58M	10.91M	-	-	-	-
Laboratory services Growth	-	17.57%	3.16%	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023
USA	-	-	-	-	-	76.62M	66.85M
USA Growth	-	-	-	-	-	-	-12.75%
Ireland	-	-	-	-	-	25.1M	12.72M
Ireland Growth	-	-	-	-	-	-	-49.32%
Americas	59.54M	57.56M	52.18M	70.41M	57.8M	-	-
Americas Growth	-	-3.33%	-9.34%	34.93%	-17.91%	-	-
Asia / Africa	27.13M	29.47M	27.69M	22.57M	25.5M	-	-
Asia / Africa Growth	-	8.61%	-6.04%	-18.49%	13.01%	-	-
Europe (including Ireland)	12.47M	10.01M	10.57M	9.01M	9.66M	-	-
Europe (including Ireland) Growth	-	-19.73%	5.55%	-14.77%	7.30%	-	-

Frequently Asked Questions

Growth & Financials

Trinity Biotech plc (TRIB) reported $49.6M in revenue for fiscal year 2024. This represents a 36% decrease from $77.9M in 2011.

Trinity Biotech plc (TRIB) grew revenue by 8.3% over the past year. This is steady growth.

Trinity Biotech plc (TRIB) reported a net loss of $36.6M for fiscal year 2024.

Dividend & Returns

Trinity Biotech plc (TRIB) had negative free cash flow of $10.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Trinity Biotech plc (TRIB) 10-Year Financial Performance & Capital Metrics

TRIB • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

Revenue $62M +8.3%
EBITDA -$19M +23.6%
Net Income -$32M -32.4%
EPS (Diluted) -1.77 +44.7%
Gross Margin 34.83% +1.8%
EBITDA Margin -31.35% +29.5%
Operating Margin -34.38% +27.7%
Net Margin -51.64% -22.2%
ROE -
ROIC -31.68% +19.4%
Debt/Equity -
Interest Coverage -2.21 +17.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 7.4% over 5 years
✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-5.19%

5Y-7.41%

3Y-8.8%

TTM-15.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM8.21%

ROCE

10Y Avg-9.51%

5Y Avg-21.65%

3Y Avg-38.26%

Latest-36.62%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	100.19M	99.61M	99.14M	97.03M	90.44M	101.98M	81.15M	62.52M	56.83M	61.55M
Revenue Growth %	-0.04%	-0.01%	-0%	-0.02%	-0.07%	0.13%	-0.2%	-0.23%	-0.09%	0.08%
Cost of Goods Sold+	53.95M	56.52M	57.25M	55.59M	52.31M	53.4M	54.89M	52.73M	37.38M	40.11M
COGS % of Revenue	0.54%	0.57%	0.58%	0.57%	0.58%	0.52%	0.68%	0.84%	0.66%	0.65%
Gross Profit+	46.24M	43.09M	41.89M	41.45M	38.12M	48.58M	33.45M	22.05M	19.45M	21.44M
Gross Margin %	0.46%	0.43%	0.42%	0.43%	0.42%	0.48%	0.41%	0.35%	0.34%	0.35%
Gross Profit Growth %	-0.08%	-0.07%	-0.03%	-0.01%	-0.08%	0.27%	-0.31%	-0.34%	-0.12%	0.1%
Operating Expenses+	32.8M	35.6M	36.41M	34.77M	32.82M	48.5M	29.52M	32.96M	46.49M	42.61M
OpEx % of Revenue	0.33%	0.36%	0.37%	0.36%	0.36%	0.48%	0.36%	0.53%	0.82%	0.69%
Selling, General & Admin	28.02M	30.8M	30.85M	29.5M	27.58M	25.07M	24.68M	29.17M	31.15M	28.82M
SG&A % of Revenue	0.28%	0.31%	0.31%	0.3%	0.31%	0.25%	0.3%	0.47%	0.55%	0.47%
Research & Development	5.07M	5.04M	5.66M	5.37M	5.33M	5.08M	4.5M	4.14M	4.38M	4.54M
R&D % of Revenue	0.05%	0.05%	0.06%	0.06%	0.06%	0.05%	0.06%	0.07%	0.08%	0.07%
Other Operating Expenses	0	0	-100K	-102K	-91K	18.34M	336K	-343K	10.96M	9.25M
Operating Income+	13.45M	7.49M	5.48M	3.3M	872K	82K	3.94M	-15.27M	-27.05M	-21.16M
Operating Margin %	0.13%	0.08%	0.06%	0.03%	0.01%	0%	0.05%	-0.24%	-0.48%	-0.34%
Operating Income Growth %	-0.25%	-0.44%	-0.27%	-0.4%	-0.74%	-0.91%	47.02%	-4.88%	-0.77%	0.22%
EBITDA+	19.09M	13.32M	10.68M	7.42M	5.77M	3.16M	6.68M	-12.94M	-25.27M	-19.3M
EBITDA Margin %	0.19%	0.13%	0.11%	0.08%	0.06%	0.03%	0.08%	-0.21%	-0.44%	-0.31%
EBITDA Growth %	-0.15%	-0.3%	-0.2%	-0.31%	-0.22%	-0.45%	1.12%	-2.94%	-0.95%	0.24%
D&A (Non-Cash Add-back)	5.64M	5.82M	5.2M	4.12M	4.89M	3.08M	2.74M	2.33M	1.78M	1.86M
EBIT	27M	-36.74M	-34.47M	-18.1M	-23.41M	118K	7.85M	-19.05M	-25.87M	-18.77M
Net Interest Income+	9.44M	-2.29M	-4.6M	-2.96M	-5.12M	-6.71M	-5.87M	-24.43M	-8.98M	-9.56M
Interest Income	12.91M	2.43M	808K	2.12M	464K	36K	1.22M	303K	1.17M	0
Interest Expense	3.48M	4.73M	5.41M	5.08M	5.58M	6.75M	7.1M	24.73M	10.15M	9.56M
Other Income/Expense	9.49M	-2.26M	-2.21M	-2.96M	-5.88M	-6.71M	-5.86M	-24.43M	-9.88M	-9.56M
Pretax Income+	22.88M	5.19M	1.6M	3.03M	821K	-6.63M	-1.92M	-43.78M	-36.93M	-30.73M
Pretax Margin %	0.23%	0.05%	0.02%	0.03%	0.01%	-0.07%	-0.02%	-0.7%	-0.65%	-0.5%
Income Tax+	1.08M	41K	-697K	637K	4.89M	-620K	-74K	-194K	-59K	486K
Effective Tax Rate %	0.95%	-19.37%	-25.11%	0.79%	-4.95%	0.96%	-0.45%	0.94%	0.65%	1.03%
Net Income+	21.8M	-100.63M	-40.27M	2.39M	-4.07M	-6.39M	875K	-41M	-24.02M	-31.79M
Net Margin %	0.22%	-1.01%	-0.41%	0.02%	-0.04%	-0.06%	0.01%	-0.66%	-0.42%	-0.52%
Net Income Growth %	0.27%	-5.62%	0.6%	1.06%	-2.7%	-0.57%	1.14%	-47.86%	0.41%	-0.32%
Net Income (Continuing)	22.19M	-38.56M	-38.66M	-22.66M	0	-6.01M	-1.85M	-43.59M	-36.87M	-31.22M
Discontinued Operations	0	0	0	568K	77K	-375K	2.73M	2.58M	12.85M	-573K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.48	-17.78	-7.49	0.46	-0.80	-1.54	0.16	-5.20	-3.20	-1.77
EPS Growth %	-0.34%	-38.04%	0.58%	1.06%	-2.74%	-0.93%	1.1%	-33.5%	0.38%	0.45%
EPS (Basic)	0.96	-21.91	-9.31	0.57	-0.97	-1.54	0.21	-6.00	-3.20	-1.77
Diluted Shares Outstanding	5.48M	5.66M	5.38M	5.18M	5.09M	4.18M	5.33M	7.77M	7.65M	17.96M
Basic Shares Outstanding	4.63M	4.59M	4.32M	4.18M	4.18M	4.18M	4.18M	6.75M	7.65M	17.96M
Dividend Payout Ratio	0.23%	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	163.23M	133.49M	112.59M	86.66M	71.39M	83.3M	72.69M	46.67M	39.04M	41.12M
Cash & Short-Term Investments	101.95M	77.11M	57.61M	30.28M	16.4M	27.33M	25.91M	6.58M	3.69M	5.17M
Cash Only	101.95M	77.11M	57.61M	30.28M	16.4M	27.33M	25.91M	6.58M	3.69M	5.17M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	20.66M	20.16M	21.29M	25.22M	22.39M	24.59M	15.71M	15.65M	13.38M	14.6M
Days Sales Outstanding	75.25	73.86	78.38	94.86	90.38	88.03	70.66	91.39	85.94	86.6
Inventory	35.13M	32.59M	32.8M	30.36M	32.02M	30.22M	29.12M	22.5M	19.93M	19.37M
Days Inventory Outstanding	237.64	210.46	209.15	199.35	223.41	206.55	193.67	155.76	194.63	176.29
Other Current Assets	0	0	0	0	0	0	0	1K	0	0
Total Non-Current Assets+	195.73M	116.1M	80.02M	64.57M	59.68M	47.1M	46.21M	45.44M	20.39M	62.17M
Property, Plant & Equipment	20.66M	13.4M	5.8M	5.36M	9.29M	8.55M	5.92M	5.68M	1.89M	4.62M
Fixed Asset Turnover	4.85x	7.43x	17.09x	18.10x	9.73x	11.93x	13.71x	11.00x	30.04x	13.32x
Goodwill	52.69M	25.77M	17.9M	16.14M	12.59M	12.59M	12.54M	12.54M	0	13.84M
Intangible Assets	108.67M	61.5M	46.86M	36.81M	31.06M	21.27M	23.44M	22.73M	16.27M	37.5M
Long-Term Investments	5.56M	792.35K	1.04M	476K	403K	441K	151K	212K	214K	2.46M
Other Non-Current Assets	-4.61M	77.65K	-274K	82K	82K	64K	56K	55K	43K	194K
Total Assets+	358.96M	249.59M	192.62M	151.24M	131.07M	130.4M	118.89M	92.1M	59.44M	103.29M
Asset Turnover	0.28x	0.40x	0.51x	0.64x	0.69x	0.78x	0.68x	0.68x	0.96x	0.60x
Asset Growth %	0.48%	-0.3%	-0.23%	-0.21%	-0.13%	-0.01%	-0.09%	-0.23%	-0.35%	0.74%
Total Current Liabilities+	20.11M	25.28M	21.23M	17.6M	19.45M	27.06M	100.49M	17.34M	15.04M	32.09M
Accounts Payable	8.33M	9.02M	8.04M	8.12M	7.83M	7.1M	6.76M	6.21M	3.88M	6.83M
Days Payables Outstanding	56.35	58.23	51.29	53.29	54.65	48.55	44.97	42.95	37.93	62.17
Short-Term Debt	0	0	0	0	2.4M	2.9M	83.31M	210K	210K	210K
Deferred Revenue (Current)	187K	224K	278K	312K	292K	1000K	141K	114K	50K	197K
Other Current Liabilities	598K	4.21M	201K	204K	-2.18M	760K	249K	153K	160K	2.57M
Current Ratio	8.12x	5.28x	5.30x	4.92x	3.67x	3.08x	0.72x	2.69x	2.60x	1.28x
Quick Ratio	6.37x	3.99x	3.76x	3.20x	2.02x	1.96x	0.43x	1.39x	1.27x	0.68x
Cash Conversion Cycle	256.54	226.09	236.23	240.91	259.14	246.03	219.35	204.2	242.63	200.71
Total Non-Current Liabilities+	124.96M	115.59M	106.19M	89.58M	106.91M	105.56M	18.72M	76.94M	68.35M	106.38M
Long-Term Debt	91.51M	92.23M	92.95M	81.38M	82.02M	82.69M	0	58.05M	54.65M	87.79M
Capital Lease Obligations	1.04M	732K	532K	526K	17.75M	16.59M	13.87M	12.27M	10.87M	10.48M
Deferred Tax Liabilities	24.82M	18.36M	10.83M	7.43M	7.14M	4.91M	4.86M	5.06M	2.3M	4.56M
Other Non-Current Liabilities	32.4M	22.62M	2.23M	8.09M	4K	1.37M	0	1.57M	526K	3.55M
Total Liabilities	145.07M	140.87M	127.42M	107.18M	126.36M	132.62M	119.21M	94.28M	83.38M	138.47M
Total Debt+	98.04M	96.49M	94.83M	81.62M	82.03M	104.34M	99.16M	72.2M	67.43M	100.76M
Net Debt	-3.91M	19.38M	37.22M	51.34M	65.63M	77.01M	73.25M	51.68M	63.74M	95.6M
Debt / Equity	0.46x	0.89x	1.45x	1.85x	17.40x	-	-	-	-	-
Debt / EBITDA	5.14x	7.25x	8.88x	11.00x	14.23x	33.03x	14.84x	-	-	-
Net Debt / EBITDA	-0.20x	1.46x	3.49x	6.92x	11.38x	24.38x	10.96x	-	-	-
Interest Coverage	3.86x	1.59x	1.01x	0.65x	0.16x	0.01x	0.55x	-0.62x	-2.67x	-2.21x
Total Equity+	213.89M	108.73M	65.2M	44.05M	4.71M	-2.22M	-319K	-2.18M	-23.95M	-35.18M
Equity Growth %	0.09%	-0.49%	-0.4%	-0.32%	-0.89%	-1.47%	0.86%	-5.82%	-10.01%	-0.47%
Book Value per Share	39.02	19.21	12.13	8.51	0.93	-0.53	-0.06	-0.28	-3.13	-1.96
Total Shareholders' Equity	213.89M	108.73M	65.2M	44.05M	4.71M	-2.22M	-319K	-2.18M	-23.95M	-35.18M
Common Stock	1.22M	1.22M	1.22M	1.22M	1.22M	1.21M	1.21M	1.96M	1.97M	4.19M
Retained Earnings	201.95M	93M	46.16M	24.37M	11.51M	10.57M	12.56M	-26.7M	-48.64M	-79.12M
Treasury Stock	-7.37M	-17.33M	-24.78M	-24.92M	-24.92M	-24.92M	-24.92M	-24.92M	-24.92M	-24.92M
Accumulated OCI	-4.81M	-1.69M	1.63M	2.27M	-24.21M	-5.27M	-5.36M	-5.69M	1.03M	-5.44M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	12.34M	13.77M	12.11M	6.93M	5.47M	23.75M	13.24M	-921K	-11.56M	-4.19M
Operating CF Margin %	0.12%	0.14%	0.12%	0.07%	0.06%	0.23%	0.16%	-0.01%	-0.2%	-0.07%
Operating CF Growth %	-0.22%	0.12%	-0.12%	-0.43%	-0.21%	3.34%	-0.44%	-1.07%	-11.55%	0.64%
Net Income	19.85M	16.25M	12.77M	13.07M	12.2M	-6.39M	875K	-41.01M	-24.02M	-31.79M
Depreciation & Amortization	5.64M	6.13M	5.2M	4.12M	4.89M	3.08M	2.74M	2.33M	1.78M	1.86M
Stock-Based Compensation	1.55M	1.41M	928K	1.37M	758K	792K	1.1M	1.75M	2.07M	1.32M
Deferred Taxes	1.08M	-8.63M	-374K	-1.11M	-1.01M	-182K	-167K	-192K	-59K	486K
Other Non-Cash Items	-8.63M	757K	-5.87M	-2.92M	-10.57M	22.31M	8.86M	37.85M	11.37M	17.74M
Working Capital Changes	-7.16M	-2.15M	-535K	-7.6M	-796K	4.14M	-172K	-1.66M	-2.69M	6.19M
Change in Receivables	-2.34M	738K	-2.37M	-5.96M	445K	-2.49M	6.24M	-966K	1.05M	-2.37M
Change in Inventory	-2.34M	-3.62M	-2.46M	1.99M	-2.96M	-3.42M	-4.41M	-877K	-971K	-1.74M
Change in Payables	-3.33M	1.27M	2.02M	-3.42M	151K	4.99M	-7.59M	181K	-2.77M	8.19M
Cash from Investing+	-22.72M	-22.28M	-16.37M	-17.29M	-15.36M	-10.2M	-8.69M	-5.98M	24.76M	-22.97M
Capital Expenditures	-22.72M	-22.28M	-16.37M	-17.29M	-15.36M	-10.2M	-8.69M	-5.98M	-803K	-405K
CapEx % of Revenue	0.23%	0.22%	0.17%	0.18%	0.17%	0.1%	0.11%	0.1%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.11M	-1.11M	-1.11M	-9.86M	0	0	0	0	-1.9M	-9.66M
Cash from Financing+	103.23M	-16.34M	-15.25M	-16.98M	-4M	-2.72M	-6.02M	-12.32M	-16.04M	28.81M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-5.1M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-6.67M	-3.75M	-4.6M	-4.5M	-463K	524K	-3.08M	-10.61M	-8.67M	-6.25M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.38M	-8.51M	-4.25M	-10.35M	-9.88M	13.56M	4.55M	-6.9M	-12.36M	-14.26M
FCF Margin %	-0.1%	-0.09%	-0.04%	-0.11%	-0.11%	0.13%	0.06%	-0.11%	-0.22%	-0.23%
FCF Growth %	-0.27%	0.18%	0.5%	-1.43%	0.05%	2.37%	-0.66%	-2.52%	-0.79%	-0.15%
FCF per Share	-1.89	-1.50	-0.79	-2.00	-1.94	3.24	0.85	-0.89	-1.61	-0.79
FCF Conversion (FCF/Net Income)	0.57x	-0.14x	-0.30x	2.90x	-1.35x	-3.72x	15.13x	0.02x	0.48x	0.13x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.61%	-62.38%	-46.31%	4.38%	-16.68%	-512.27%	-	-	-	-
Return on Invested Capital (ROIC)	5.07%	3.32%	3.56%	2.5%	0.79%	0.08%	4%	-16.79%	-39.3%	-31.68%
Gross Margin	46.16%	43.26%	42.25%	42.72%	42.15%	47.64%	41.23%	35.27%	34.22%	34.83%
Net Margin	21.75%	-101.02%	-40.62%	2.46%	-4.5%	-6.26%	1.08%	-65.58%	-42.26%	-51.64%
Debt / Equity	0.46x	0.89x	1.45x	1.85x	17.40x	-	-	-	-	-
Interest Coverage	3.86x	1.59x	1.01x	0.65x	0.16x	0.01x	0.55x	-0.62x	-2.67x	-2.21x
FCF Conversion	0.57x	-0.14x	-0.30x	2.90x	-1.35x	-3.72x	15.13x	0.02x	0.48x	0.13x
Revenue Growth	-4.46%	-0.58%	-0.47%	-2.12%	-6.8%	12.77%	-20.43%	-22.96%	-9.1%	8.31%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023
Point-of-Care	16.77M	14.84M	11.39M	9.21M	10.34M	9.21M	9.09M
Point-of-Care Growth	-	-11.55%	-23.21%	-19.12%	12.18%	-10.87%	-1.32%
Clinical laboratory goods	-	-	-	84.28M	74.7M	-	-
Clinical laboratory goods Growth	-	-	-	-	-11.37%	-	-
Clinical laboratory services	-	-	-	8.48M	7.93M	-	-
Clinical laboratory services Growth	-	-	-	-	-6.56%	-	-
Clinical laboratory	73.37M	71.62M	68.13M	-	-	-	-
Clinical laboratory Growth	-	-2.38%	-4.87%	-	-	-	-
Laboratory services	9M	10.58M	10.91M	-	-	-	-
Laboratory services Growth	-	17.57%	3.16%	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023
USA	-	-	-	-	-	76.62M	66.85M
USA Growth	-	-	-	-	-	-	-12.75%
Ireland	-	-	-	-	-	25.1M	12.72M
Ireland Growth	-	-	-	-	-	-	-49.32%
Americas	59.54M	57.56M	52.18M	70.41M	57.8M	-	-
Americas Growth	-	-3.33%	-9.34%	34.93%	-17.91%	-	-
Asia / Africa	27.13M	29.47M	27.69M	22.57M	25.5M	-	-
Asia / Africa Growth	-	8.61%	-6.04%	-18.49%	13.01%	-	-
Europe (including Ireland)	12.47M	10.01M	10.57M	9.01M	9.66M	-	-
Europe (including Ireland) Growth	-	-19.73%	5.55%	-14.77%	7.30%	-	-

Frequently Asked Questions

Growth & Financials

Trinity Biotech plc (TRIB) reported $49.6M in revenue for fiscal year 2024. This represents a 36% decrease from $77.9M in 2011.

Trinity Biotech plc (TRIB) grew revenue by 8.3% over the past year. This is steady growth.

Trinity Biotech plc (TRIB) reported a net loss of $36.6M for fiscal year 2024.

Dividend & Returns

Trinity Biotech plc (TRIB) had negative free cash flow of $10.4M in fiscal year 2024, likely due to heavy capital investments.